Premium
Immunological reclassification of 22 children with a former diagnosis of non‐T, non‐B ALL
Author(s) -
Fugger Lars,
Platz Per,
Ryder Lars,
Svejgaard Arne,
Heldrup Jesper,
Hertz Henrik,
Yssing Minna
Publication year - 1987
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1987.tb00785.x
Subject(s) - cd19 , b cell , medicine , immunophenotyping , cd20 , bone marrow , peripheral blood mononuclear cell , monoclonal antibody , immunology , flow cytometry , antigen , antibody , biology , genetics , in vitro
Stored peripheral blood or bone marrow mononuclear cells from 22 pediatric patients with verified acute lymphoblastic leukemia (ALL) previously classified as non‐T, non‐B ALL were re‐investigated by flow cytometric analysis by means of a panel of B cell‐specific and ‐associated monoclonal antibodies (moabs) using a new analytical method described by Platz et al, the so‐called Delta Channel Value method. All 22 patients were immunologically re‐characterized as pre‐B ALL. The reproducibility between the first (acute) and subsequent re‐analysis was almost complete. 20 of the tumor cell populations could be assigned to the B cell differentiation scheme recently proposed by Nadler et al. This scheme operates with four stages of pre‐B cell differentiation and each stage is defined by the expression of one to four of the following markers: HLA‐DR, CD19, CD10 and CD20. Two additional markers, CD24 and CD22, were investigated in our study and allowed further subdivision of the four subgroups proposed by Nadler et al. The composition of a panel of moabs for routine classification of pre‐B ALL is proposed.